Medicinal Chemistry Research Program (Project-003)

药物化学研究计划（Project-003）

• 批准号: 8855805
• 负责人: DEBORAH W KNAPP
• 金额: $ 2.66万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8855805
• 关键词: Antineoplastic Agents; Award; Basic Science; Cancer Center Support Grant; Canis familiaris; Cells; Chemicals; Clinic; Collaborations; Development; Discipline; Drug Delivery Systems; Evaluation; Extramural Activities; Faculty; Funding; Grant; Human; In Vitro; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Mentors; Methods; Modeling; Molecular; NCI Center for Cancer Research; Paper; Peer Review; Pharmaceutical Chemistry; Phase; Phase III Clinical Trials; Program Research Project Grants; Publications; Recruitment Activity; Research; Research Personnel; Signal Transduction; Structure; Technology; Therapeutic Agents; Translations; Universities; anti-cancer therapeutic; base; college; comparative; drug discovery; in vivo; in vivo Model; meetings; member; novel; oncology; pre-clinical; programs; protein protein interaction; screening; structural biology; tool

Medicinal Chemistry Research Program: Project Summary The Medicinal Chemistry Program (MC) in the Purdue University Center for Cancer Research (PCCR) drives the drug discovery effort of the Center by serving as the central component for basic research in cancer drug discovery and drug discovery methods. The Program consists of 23 members who integrate their expertise in novel synthetic strategies and advanced technologies with the other Research Programs in the Center, to advance translation of promising entities to the clinic. During the past four years, nine new cancer- focused faculty members were recruited to the MC Program. MC members are united by a focus on cancer drug discovery, and represent diverse disciplines that are drawn from seven academic departments and four colleges from across the Purdue campus. The MC Program has a strong publication record, producing 286 papers between 2010 and 2013 with 2% involving intra-programmatic collaborations, 19% representing inter- programmatic and 21% engaging inter-institutional partners; overall, 39% MC publications were a result of collaborative efforts with other cancer researchers. Combined, the MC membership has a current portfolio of over $1.7 million of total direct peer-reviewed, extramural support, with 44% of awards being cancer-focused grants funded by the NCI, NSF, ACS or DOD. The MC Program is structured around two Research Clusters. Research Cluster 1, Synthetic Medicinal Chemistry, and the cornerstone of the MC Program, reflects the strengths of the Center in medicinal chemistry. A distinguished group of senior and junior faculty develops and utilizes target-based medicinal chemistry approaches to drug discovery. The efforts of this group have led to the development of 13 agents that have been in Phase 0, Phase I, Phase II, or Phase III clinical trials in the last funding cycle. Ten other agents have progressed to preclinical development (in vivo studies). Research Cluster 2, Target Discovery and Translation, encompasses a focus on target discovery, in vitro and in cell molecular evaluation of potential anti-cancer therapeutic agents, and the development and use of in vivo models and methods for the analysis of potential anti-cancer drugs. Tools have been developed for high- throughput single cell screening as well as in cell sensing and identifying protein-protein interaction networks. There is a specific emphasis on comparative oncology including studies of dogs with naturally-occurring cancers that closely mimic the human condition. The canine models are being evaluated for their impact on the translation of therapeutic agents to humans. Over the past four years, many MC projects have spawned highly productive inter-programmatic collaborations involving members of the Cell Identity and Signaling (CIS), Chemical and Structural Biology (CSB), and Drug Delivery and Molecular Sensing (DDMS) Programs. The Program Leader and Co-Leader's efforts in cancer-focused faculty recruiting and mentoring, and organizing Program meetings and the PCCR-based Bladder Cancer Discovery Group, have enhanced the two Research Clusters and overall research progress of the MC Program.

药物化学研究计划： 项目摘要 普渡大学癌症研究中心（PCCR）的药物化学计划（MC） 通过作为癌症基础研究的核心组成部分来驱动中心的药物发现工作 药物发现和药物发现方法。该计划由23名成员组成 与其他研究计划的新型合成策略和先进技术方面的专业知识 中心，以推动有前途的实体翻译到诊所。在过去的四年中，九个新癌症 - 专注的教职员工被招募到MC计划。 MC成员团结于癌症。 毒品发现，并代表来自七个学术部门和四个学科的各种学科 来自普渡大学校园的大学。 MC计划具有强大的出版记录，产生286 2010年至2013年之间的论文涉及2％的涉及前编程的合作，有19％代表相互作用 程序化和21％与机构间合作伙伴的参与；总体而言，39％的MC出版物是 与其他癌症研究人员的合作努力。 MC会员合并有一个目前的投资组合 超过170万美元的直接同行评审，外壁外支持，有44％的奖项是以癌为中心的 由NCI，NSF，ACS或DOD资助的赠款。 MC计划围绕两个研究集群结构。 研究集群1，合成药物化学和MC计划的基石，反映了 中心在药物化学方面的优势。一组杰出的高级和初级教师发展， 利用基于目标的药物化学方法来发现药物。该小组的努力导致了 在第0阶段，第一阶段，II期或III期临床试验中的13种药物的发展 最后的资金周期。其他十个代理已经发展为临床前发展（体内研究）。研究 群集2，目标发现和翻译，涵盖了目标发现，体外和细胞中的重点 潜在抗癌治疗剂的分子评估以及体内的发展和使用 分析潜在抗癌药物的模型和方法。已经开发了用于高级的工具 吞吐量单细胞筛选以及细胞传感和识别蛋白质 - 蛋白质相互作用网络。 特定的重点是比较肿瘤学，包括对自然存在的狗的研究 紧密模仿人类状况的癌症。正在评估犬类模型的影响 将治疗剂翻译为人类。在过去的四年中，许多MC项目都产生了高度 涉及细胞身份和信号的成员（CI）的生产性跨编程合作， 化学和结构生物学（CSB）以及药物输送和分子传感（DDMS）程序。这 计划负责人和联合领导者在以癌症为中心的教师招募和指导方面的努力，并组织 计划会议和基于PCCR的膀胱癌发现组，增强了两项研究 集群和MC计划的整体研究进度。